Insulin Applications Intended For Biosimilar Pathway May Already Be At US FDA

In congressional testimony, outgoing Commissioner Scott Gottlieb says FDA already has "a lot of applications in-house" and robust interest when asked about the 2020 transition of insulin from regulation as a drug to a biologic.

LI-2 Protein_564977620_1200.jpg

Outgoing US FDA Commissioner Scott Gottlieb implied that applications for follow-on insulins already may be arriving at the agency as part of a flurry of activity in anticipation of the opening of the biosimilar pathway to the products.

Insulin is among the products currently regulated as a drug that on March 23, 2020 will be deemed a biologic,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics